Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

Aspartame linked to surging insulin levels, fatty plaques and inflammation

Aspartame, the artificial sweetener commonly found in diet sodas and sugar-free snacks, may do significant harm to a person’s cardiovascular system.

Thumbnail

Data trove of 1.6M patient records discovered online

A cybersecurity researcher made the discovery. The database, in the care of a clinical trials company, was not password protected or encrypted. 

heart drugs with stethoscope

Sotagliflozin the first drug of its kind to limit heart attacks, strokes in high-risk patients

Sotagliflozin, a dual SGLTI and SGLT2 inhibitor, can significantly reduce the risk of adverse cardiovascular events in patients with type 2 diabetes, CKD and additional cardiovascular risk factors, according to a new study of more than 10,000 patients. 

White matter hyperintensities might not be a marker of TBI after all

New findings are calling into question the notion that white matter hyperintensities are biomarkers of brain injuries. 

CABG coronary artery bypass grafting heart surgery

CABG still the ‘gold standard’ for revascularization in patients with 3-vessel CAD and CKD

The median follow-up period was more than nine years, allowing researchers to compare long-term outcomes after both CABG and PCI. 

pharmaceutical drug approval process

Osteoporosis drug shows potential to treat heart disease

Researchers used advanced AI to see if any FDA-approved medications could potentially reverse one of the mutations behind dilated cardiomyopathy. Risedronate, a popular osteoporosis medication, is the one candidate that got the job done.

Biosense Webster, part of Johnson & Johnson MedTech, shared updated data on its Varipulse pulsed field ablation (PFA) system at AF Symposium 2024 in Boston,

Johnson & Johnson resumes PFA rollout after stopping to review safety concerns

Johnson & Johnson MedTech has resumed the U.S. rollout of its Varipulse PFA system, sharing new warnings to help physicians. 

Thumbnail

Veterans with heart disease often receive better care through VA than they would elsewhere

Military veterans face an increased risk of cardiovascular disease, making it especially important to ensure they receive high-quality care.